Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | YWHAH | Q04917 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | UBE2N | P61088 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12665252 | 0.88 | CYP2C8 (0.42) | CYP2C8KMT2ABRD4MCHR1MEN1 | |
| SCHEMBL832184 | 0.88 | CYP2C8 (0.40) | CYP2C8KMT2AYWHAHMEN1 | |
| SCHEMBL12665133 | 0.87 | CYP2C8 (0.54) | CYP2C8KMT2AYWHAHMEN1LMNA | |
| SCHEMBL830714 | 0.86 | CYP2C8 (0.42) | CYP2C8KMT2AYWHAHMEN1MAPT | |
| SCHEMBL831710 | 0.77 | CYP2C8 (0.43) | CYP2C8KMT2AMEN1MAPT | |
| SCHEMBL831674 | 0.77 | CYP2C8 (0.43) | CYP2C8KMT2AMEN1MAPT | |
| SCHEMBL862159 | 0.77 | KMT2A (0.42) | CYP2C8KMT2AMCHR1MEN1MAPT | |
| SCHEMBL831703 | 0.77 | CYP2C8 (0.44) | CYP2C8KMT2AMEN1MAPTTP53 | |
| SCHEMBL830899 | 0.76 | CYP2C8 (0.45) | CYP2C8KMT2AMEN1MAPTPOLB | |
| SCHEMBL831764 | 0.76 | CYP2C8 (0.42) | CYP2C8KMT2AMEN1MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110104110-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SHERING CORPORATION | 2011-05-05 | — | — | US | disclosed |
| US-20110104110-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SHERING CORPORATION | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104110-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, INMT | CYP2C8 457/4885KMT2A 537/4885YWHAH 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.